+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Respiratory Disease Testing Market - Global Forecast 2026-2032- Product Image
Respiratory Disease Testing Market - Global Forecast 2026-2032- Product Image
Sale

Respiratory Disease Testing Market - Global Forecast 2026-2032

  • Report

  • 193 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 6012368
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Respiratory Disease Testing Market is projected to reach USD 6.34 Billion in 2026. It is expected to continue growing at a CAGR of 6.50%, reaching USD 9.32 Billion by 2032.

Respiratory disease testing has become a core pillar of clinical decision-making, public health surveillance, antimicrobial stewardship, and outbreak preparedness. Demand is supported by the persistent burden of influenza, respiratory syncytial virus (RSV), tuberculosis, COVID-19, pneumonia, asthma and COPD exacerbations, and emerging respiratory pathogens. The World Health Organization reports tuberculosis remains one of the world’s leading infectious disease killers, with an estimated 10.8 million people developing TB in 2023, underscoring the ongoing need for rapid, accurate respiratory diagnostics.

The market is shifting from centralized, single-pathogen testing toward integrated molecular panels, point-of-care antigen and molecular platforms, syndromic testing, and digitally connected diagnostics. Hospitals, reference laboratories, urgent care centers, pharmacies, and home-care settings are increasingly evaluating respiratory disease testing solutions based on speed, sensitivity, workflow efficiency, reimbursement fit, specimen type, and the ability to support surveillance reporting.

Transformative Shifts in the Respiratory Testing Landscape

The respiratory disease testing landscape is being reshaped by the normalization of molecular diagnostics after the COVID-19 pandemic, expanded multiplex PCR adoption, and rising demand for decentralized testing. Clinical buyers are prioritizing platforms that can differentiate viral and bacterial etiologies quickly, reducing inappropriate antibiotic use and improving patient triage during seasonal surges.

A second transformative shift is the convergence of diagnostics with digital health infrastructure. Laboratories and providers are integrating respiratory test results with electronic health records, public health reporting systems, and population-level dashboards. This creates competitive advantage for solutions that combine analytical accuracy with connectivity, automation, sample-to-answer workflows, and scalable supply chains.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is having a cumulative impact across respiratory disease testing by improving image interpretation, symptom triage, laboratory workflow optimization, epidemiological forecasting, and quality control. AI-enabled chest imaging tools can help prioritize suspected pneumonia, tuberculosis, and COVID-19 cases, while machine learning models support earlier detection of outbreak signals from testing volumes, positivity rates, syndromic data, and wastewater surveillance inputs.

The most commercially relevant AI use cases are those that reduce operational burden without replacing laboratory-grade validation. In practice, AI strengthens demand forecasting, reagent inventory planning, result interpretation support, and clinical decision support when paired with regulated diagnostic platforms. Industry leaders must ensure models are transparent, validated across diverse populations, and aligned with privacy, cybersecurity, and medical device regulations.

Key Regional Insights

Asia-Pacific is one of the most dynamic regions for respiratory disease testing due to large patient populations, high tuberculosis burden in several countries, urban air pollution, aging demographics in developed markets, and expanding healthcare access. China, India, Japan, South Korea, and Australia are investing in molecular diagnostics, public health surveillance, and hospital laboratory modernization, while Southeast Asian markets are increasing adoption of rapid tests for influenza, COVID-19, RSV, and TB screening in both centralized and community settings.

North America remains a high-value region driven by established reimbursement pathways, advanced molecular testing capacity, strong hospital networks, and high awareness of respiratory viruses. Latin America is expanding diagnostic access through public procurement, private laboratory networks, and infectious disease surveillance programs, with Brazil and Mexico serving as major demand centers. Europe benefits from strong regulatory oversight, mature laboratory infrastructure, antimicrobial resistance initiatives, and coordinated surveillance through national agencies and the European Centre for Disease Prevention and Control.

The Middle East is investing in hospital modernization, medical tourism infrastructure, and national preparedness programs, particularly across Gulf markets where advanced laboratory platforms are increasingly embedded in tertiary care systems. Africa presents significant long-term need because of the high burden of TB, pneumonia, HIV-associated respiratory infections, and limited laboratory access in many countries; scalable point-of-care testing, specimen referral networks, mobile diagnostics, and donor-supported programs are central to improving diagnostic coverage.

Key Group Insights

ASEAN markets are characterized by diverse healthcare systems, rising urbanization, cross-border mobility, and growing demand for affordable respiratory diagnostics that can operate in both hospital and decentralized settings. The GCC is accelerating adoption of advanced molecular platforms through healthcare transformation programs, centralized procurement, digital health investment, and expansion of high-acuity hospitals.

The European Union supports respiratory disease testing through harmonized regulatory frameworks, antimicrobial resistance strategies, clinical laboratory quality standards, and cross-border surveillance capacity. BRICS economies collectively represent large-volume opportunities because of population scale, infectious disease burden, expanding domestic manufacturing capabilities, and growing investment in public health laboratories. G7 countries remain innovation hubs for multiplex molecular testing, companion digital tools, regulatory science, and reimbursement-backed clinical adoption, while NATO-aligned health systems increasingly view respiratory pathogen detection as part of health security, military readiness, emergency preparedness, and continuity of essential services.

Key Country Insights

The United States leads in commercial adoption of multiplex respiratory panels, point-of-care molecular systems, and pharmacy-based testing expansion, supported by large laboratory networks, established coding pathways, and strong seasonal demand. Canada emphasizes public health testing, equitable access, and provincial procurement models, while Mexico is expanding private diagnostics and public surveillance capacity. Brazil is a key Latin American demand center, with testing shaped by urban population density, influenza seasonality, TB burden, and public-private laboratory expansion.

In Europe, the United Kingdom, Germany, France, Italy, and Spain maintain strong respiratory testing ecosystems through national health systems, reference laboratories, and surveillance networks. Germany and France are particularly important for laboratory automation and molecular diagnostics, while the United Kingdom strengthened genomic and respiratory surveillance infrastructure after COVID-19. Russia remains relevant because of TB burden, respiratory infection surveillance needs, and domestic diagnostic capacity.

China and India are central to global testing volume due to population scale, TB and respiratory infection burden, air pollution-related respiratory illness, and expanding molecular testing infrastructure. Japan prioritizes high-quality diagnostics for aging populations and seasonal respiratory virus management, while South Korea combines strong biotechnology capacity with rapid adoption of advanced testing. Australia benefits from robust public health surveillance, hospital testing capacity, and demand for respiratory diagnostics across both urban centers and remote healthcare settings.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated respiratory disease testing portfolios that balance speed, accuracy, cost, and clinical utility. Multiplex panels should be aligned with local epidemiology, clinical guidelines, and reimbursement realities, while point-of-care platforms should be designed for simple workflows, minimal hands-on time, broad specimen compatibility, and reliable performance during seasonal demand spikes.

Organizations should strengthen supply chain resilience for swabs, reagents, cartridges, controls, and critical plastics; invest in interoperability with laboratory information systems and electronic health records; and build evidence packages that demonstrate reduced time to diagnosis, improved patient isolation decisions, fewer unnecessary antibiotics, and better antimicrobial stewardship. Partnerships with hospitals, public health agencies, pharmacies, primary care networks, and telehealth providers can accelerate access while improving surveillance value.

Research Methodology

This executive summary is developed using a structured secondary research methodology that triangulates information from public health agencies, regulatory bodies, peer-reviewed literature, clinical guidelines, and international disease surveillance sources. Key reference points include the World Health Organization, U.S. Centers for Disease Control and Prevention, European Centre for Disease Prevention and Control, national health ministries, and published diagnostic performance studies.

Market interpretation applies qualitative and quantitative validation across disease burden, testing settings, technology adoption, reimbursement dynamics, procurement behavior, regulatory pathways, and regional healthcare infrastructure. Insights are reviewed for consistency, recency, and relevance to respiratory disease testing, with emphasis on verified trends, epidemiological evidence, and clinically validated diagnostic use cases rather than speculative claims.

Conclusion

Respiratory disease testing is evolving into a connected, multi-technology ecosystem that supports faster diagnosis, better treatment decisions, stronger antimicrobial stewardship, and more resilient public health response. The market’s next phase will be defined by multiplex molecular adoption, decentralized access, AI-supported workflows, and integration with surveillance systems.

Organizations that combine clinically validated assays, scalable manufacturing, digital connectivity, regulatory discipline, and region-specific commercialization strategies will be best positioned to capture growth opportunities. As respiratory pathogens continue to create seasonal, endemic, and pandemic risks, accurate and accessible testing will remain essential to healthcare resilience worldwide.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Respiratory Disease Testing Market, by Component
7.1. Introduction
7.2. Instruments
7.3. Reagents & Kits
7.4. Software
7.5. Services
8. Respiratory Disease Testing Market, by Test Type
8.1. Introduction
8.2. Molecular Diagnostics
8.2.1. Polymerase Chain Reaction (PCR)
8.2.2. Next Generation Sequencing (NGS)
8.2.3. Loop Mediated Isothermal Amplification (LAMP)
8.3. Imaging Tests
8.3.1. Chest X Ray
8.3.2. Computed Tomography
8.3.3. Magnetic Resonance Imaging (MRI)
8.3.4. Positron Emission Tomography (PET)
8.4. Immunoassays
8.4.1. Enzyme Linked Immunosorbent Assay (ELISA)
8.4.2. Chemiluminescence Immunoassay (CLIA)
8.4.3. Fluorescence Immunoassay
8.4.4. Radioimmunoassay (RIA)
8.5. Pulmonary Function Tests
8.5.1. Spirometry
8.5.2. Peak Flow Meter
8.5.3. Diffusion Capacity Test (DLCO)
8.6. Point of Care Testing (POCT)
9. Respiratory Disease Testing Market, by Sample Type
9.1. Introduction
9.2. Respiratory Specimens
9.2.1. Sputum
9.2.2. Bronchoalveolar Lavage (BAL)
9.2.3. Tracheal Aspirate
9.2.4. Nasopharyngeal Swab
9.3. Blood Based Samples
9.3.1. Whole Blood
9.3.2. Serum
9.3.3. Plasma
9.4. Pleural Fluid
10. Respiratory Disease Testing Market, by Age Group
10.1. Introduction
10.2. Adults
10.3. Geriatrics
10.4. Pediatrics
11. Respiratory Disease Testing Market, by Diseases Type
11.1. Introduction
11.2. Viral Respiratory Diseases
11.2.1. COVID-19
11.2.2. Influenza Infections
11.2.2.1. Influenza A
11.2.2.2. Influenza B
11.2.3. Rhinovirus Infection
11.2.4. Adenovirus Infection
11.3. Bacterial Respiratory Diseases
11.3.1. Mycobacterium Tuberculosis Infection
11.3.2. Streptococcus Pneumoniae Infection
11.3.3. Haemophilus Influenzae Infection
11.3.4. Legionella Pneumophila Infection
11.4. Fungal Respiratory Diseases
11.4.1. Aspergillus Infection
11.4.2. Cryptococcus Infection
11.4.3. Histoplasma Infection
12. Respiratory Disease Testing Market, by End Users
12.1. Introduction
12.2. Diagnostic Laboratories
12.3. Home Care Settings
12.4. Hospitals & Clinics
12.5. Research Laboratories
13. Respiratory Disease Testing Market, by Region
13.1. Asia-Pacific
13.2. North America
13.3. Latin America
13.4. Europe
13.5. Middle East
13.6. Africa
14. Respiratory Disease Testing Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Respiratory Disease Testing Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Abbott Laboratories
17.2. Becton, Dickinson and Company
17.3. Bio-Rad Laboratories, Inc.
17.4. bioMérieux SA
17.5. COSMED Srl
17.6. Danaher Corporation
17.7. DiaSorin S.p.A.
17.8. Drägerwerk AG & Co. KGaA
17.9. F. Hoffmann-La Roche Ltd.
17.10. Fisher & Paykel Healthcare Corporation Limited
17.11. GE HealthCare Technologies Inc.
17.12. Hologic, Inc.
17.13. Masimo Corporation
17.14. Medtronic plc
17.15. MGC Diagnostics Corporation
17.16. NDD Medical Technologies
17.17. Owlstone Medical Ltd.
17.18. QIAGEN N.V.
17.19. QuidelOrtho Corporation
17.20. Randox Laboratories Ltd.
17.21. ResMed Inc.
17.22. Seegene Inc.
17.23. Siemens Healthineers AG
17.24. Sysmex Corporation
17.25. Thermo Fisher Scientific Inc.
17.26. Verisante Technology, Inc.
17.27. Visby Medical, Inc.
17.28. Vyaire Medical Inc.
List of Figures
FIGURE 1. GLOBAL RESPIRATORY DISEASE TESTING MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL RESPIRATORY DISEASE TESTING MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL RESPIRATORY DISEASE TESTING MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL RESPIRATORY DISEASE TESTING MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2025 VS 2032 (%)
FIGURE 7. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2025 VS 2032 (%)
FIGURE 13. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2025 VS 2032 (%)
FIGURE 15. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2025 VS 2032 (%)
FIGURE 17. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL RESPIRATORY DISEASE TESTING MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL RESPIRATORY DISEASE TESTING MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL RESPIRATORY DISEASE TESTING MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL INSTRUMENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL INSTRUMENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL INSTRUMENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL REAGENTS & KITS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL REAGENTS & KITS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL REAGENTS & KITS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL SOFTWARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL SOFTWARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL SOFTWARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL SERVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL SERVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL SERVICES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL POLYMERASE CHAIN REACTION (PCR) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL POLYMERASE CHAIN REACTION (PCR) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL POLYMERASE CHAIN REACTION (PCR) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL LOOP MEDIATED ISOTHERMAL AMPLIFICATION (LAMP) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL LOOP MEDIATED ISOTHERMAL AMPLIFICATION (LAMP) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL LOOP MEDIATED ISOTHERMAL AMPLIFICATION (LAMP) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL IMAGING TESTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL IMAGING TESTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL IMAGING TESTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL CHEST X RAY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL CHEST X RAY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL CHEST X RAY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL COMPUTED TOMOGRAPHY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL COMPUTED TOMOGRAPHY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL COMPUTED TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL MAGNETIC RESONANCE IMAGING (MRI) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL MAGNETIC RESONANCE IMAGING (MRI) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL MAGNETIC RESONANCE IMAGING (MRI) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL POSITRON EMISSION TOMOGRAPHY (PET) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL POSITRON EMISSION TOMOGRAPHY (PET) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL POSITRON EMISSION TOMOGRAPHY (PET) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL IMMUNOASSAYS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL IMMUNOASSAYS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL IMMUNOASSAYS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL CHEMILUMINESCENCE IMMUNOASSAY (CLIA) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL CHEMILUMINESCENCE IMMUNOASSAY (CLIA) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL CHEMILUMINESCENCE IMMUNOASSAY (CLIA) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL FLUORESCENCE IMMUNOASSAY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL FLUORESCENCE IMMUNOASSAY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL FLUORESCENCE IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL RADIOIMMUNOASSAY (RIA) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL RADIOIMMUNOASSAY (RIA) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL RADIOIMMUNOASSAY (RIA) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL PULMONARY FUNCTION TESTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL PULMONARY FUNCTION TESTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL PULMONARY FUNCTION TESTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL SPIROMETRY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL SPIROMETRY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL SPIROMETRY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL PEAK FLOW METER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL PEAK FLOW METER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL PEAK FLOW METER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL DIFFUSION CAPACITY TEST (DLCO) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL DIFFUSION CAPACITY TEST (DLCO) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL DIFFUSION CAPACITY TEST (DLCO) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL POINT OF CARE TESTING (POCT) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL POINT OF CARE TESTING (POCT) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL POINT OF CARE TESTING (POCT) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL RESPIRATORY SPECIMENS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL RESPIRATORY SPECIMENS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL RESPIRATORY SPECIMENS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL SPUTUM MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL SPUTUM MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL SPUTUM MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL BRONCHOALVEOLAR LAVAGE (BAL) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL BRONCHOALVEOLAR LAVAGE (BAL) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL BRONCHOALVEOLAR LAVAGE (BAL) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL TRACHEAL ASPIRATE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL TRACHEAL ASPIRATE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL TRACHEAL ASPIRATE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL NASOPHARYNGEAL SWAB MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL NASOPHARYNGEAL SWAB MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL NASOPHARYNGEAL SWAB MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL BLOOD BASED SAMPLES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL BLOOD BASED SAMPLES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL BLOOD BASED SAMPLES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL WHOLE BLOOD MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL WHOLE BLOOD MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL WHOLE BLOOD MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL SERUM MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL SERUM MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL SERUM MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL PLASMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL PLASMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL PLASMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL PLEURAL FLUID MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL PLEURAL FLUID MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL PLEURAL FLUID MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL ADULTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL ADULTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL ADULTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL GERIATRICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL GERIATRICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL GERIATRICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL PEDIATRICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL PEDIATRICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL PEDIATRICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL VIRAL RESPIRATORY DISEASES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL VIRAL RESPIRATORY DISEASES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL VIRAL RESPIRATORY DISEASES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL COVID-19 MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL COVID-19 MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 121. GLOBAL COVID-19 MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL INFLUENZA INFECTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 123. GLOBAL INFLUENZA INFECTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 124. GLOBAL INFLUENZA INFECTIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 125. GLOBAL INFLUENZA A MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 126. GLOBAL INFLUENZA A MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 127. GLOBAL INFLUENZA A MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 128. GLOBAL INFLUENZA B MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 129. GLOBAL INFLUENZA B MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 130. GLOBAL INFLUENZA B MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 131. GLOBAL RHINOVIRUS INFECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 132. GLOBAL RHINOVIRUS INFECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 133. GLOBAL RHINOVIRUS INFECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 134. GLOBAL ADENOVIRUS INFECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 135. GLOBAL ADENOVIRUS INFECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 136. GLOBAL ADENOVIRUS INFECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 137. GLOBAL BACTERIAL RESPIRATORY DISEASES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 138. GLOBAL BACTERIAL RESPIRATORY DISEASES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 139. GLOBAL BACTERIAL RESPIRATORY DISEASES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 140. GLOBAL MYCOBACTERIUM TUBERCULOSIS INFECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 141. GLOBAL MYCOBACTERIUM TUBERCULOSIS INFECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 142. GLOBAL MYCOBACTERIUM TUBERCULOSIS INFECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 143. GLOBAL STREPTOCOCCUS PNEUMONIAE INFECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 144. GLOBAL STREPTOCOCCUS PNEUMONIAE INFECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 145. GLOBAL STREPTOCOCCUS PNEUMONIAE INFECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 146. GLOBAL HAEMOPHILUS INFLUENZAE INFECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 147. GLOBAL HAEMOPHILUS INFLUENZAE INFECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 148. GLOBAL HAEMOPHILUS INFLUENZAE INFECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 149. GLOBAL LEGIONELLA PNEUMOPHILA INFECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 150. GLOBAL LEGIONELLA PNEUMOPHILA INFECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 151. GLOBAL LEGIONELLA PNEUMOPHILA INFECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 152. GLOBAL FUNGAL RESPIRATORY DISEASES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 153. GLOBAL FUNGAL RESPIRATORY DISEASES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 154. GLOBAL FUNGAL RESPIRATORY DISEASES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 155. GLOBAL ASPERGILLUS INFECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 156. GLOBAL ASPERGILLUS INFECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 157. GLOBAL ASPERGILLUS INFECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 158. GLOBAL CRYPTOCOCCUS INFECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 159. GLOBAL CRYPTOCOCCUS INFECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 160. GLOBAL CRYPTOCOCCUS INFECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 161. GLOBAL HISTOPLASMA INFECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 162. GLOBAL HISTOPLASMA INFECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 163. GLOBAL HISTOPLASMA INFECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 164. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 165. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 166. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 167. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 168. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 169. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 170. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 171. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 172. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 173. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 174. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 175. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 176. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 177. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 178. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 179. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2017-2032 (USD MILLION)
TABLE 180. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 181. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 182. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 183. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, 2017-2032 (USD MILLION)
TABLE 184. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY PULMONARY FUNCTION TESTS, 2017-2032 (USD MILLION)
TABLE 185. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 186. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY RESPIRATORY SPECIMENS, 2017-2032 (USD MILLION)
TABLE 187. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY BLOOD BASED SAMPLES, 2017-2032 (USD MILLION)
TABLE 188. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 189. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2017-2032 (USD MILLION)
TABLE 190. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY VIRAL RESPIRATORY DISEASES, 2017-2032 (USD MILLION)
TABLE 191. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFLUENZA INFECTIONS, 2017-2032 (USD MILLION)
TABLE 192. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY BACTERIAL RESPIRATORY DISEASES, 2017-2032 (USD MILLION)
TABLE 193. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY FUNGAL RESPIRATORY DISEASES, 2017-2032 (USD MILLION)
TABLE 194. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 195. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 196. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2017-2032 (USD MILLION)
TABLE 197. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 198. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 199. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 200. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, 2017-2032 (USD MILLION)
TABLE 201. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY PULMONARY FUNCTION TESTS, 2017-2032 (USD MILLION)
TABLE 202. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 203. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY RESPIRATORY SPECIMENS, 2017-2032 (USD MILLION)
TABLE 204. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY BLOOD BASED SAMPLES, 2017-2032 (USD MILLION)
TABLE 205. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 206. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2017-2032 (USD MILLION)
TABLE 207. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY VIRAL RESPIRATORY DISEASES, 2017-2032 (USD MILLION)
TABLE 208. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFLUENZA INFECTIONS, 2017-2032 (USD MILLION)
TABLE 209. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY BACTERIAL RESPIRATORY DISEASES, 2017-2032 (USD MILLION)
TABLE 210. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY FUNGAL RESPIRATORY DISEASES, 2017-2032 (USD MILLION)
TABLE 211. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 212. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 213. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2017-2032 (USD MILLION)
TABLE 214. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 215. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 216. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 217. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, 2017-2032 (USD MILLION)
TABLE 218. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY PULMONARY FUNCTION TESTS, 2017-2032 (USD MILLION)
TABLE 219. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 220. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY RESPIRATORY SPECIMENS, 2017-2032 (USD MILLION)
TABLE 221. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY BLOOD BASED SAMPLES, 2017-2032 (USD MILLION)
TABLE 222. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 223. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2017-2032 (USD MILLION)
TABLE 224. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY VIRAL RESPIRATORY DISEASES, 2017-2032 (USD MILLION)
TABLE 225. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFLUENZA INFECTIONS, 2017-2032 (USD MILLION)
TABLE 226. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY BACTERIAL RESPIRATORY DISEASES, 2017-2032 (USD MILLION)
TABLE 227. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY FUNGAL RESPIRATORY DISEASES, 2017-2032 (USD MILLION)
TABLE 228. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 229. EUROPE RESPIRATORY DISEASE TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 230. EUROPE RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2017-2032 (USD MILLION)
TABLE 231. EUROPE RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 232. EUROPE RESPIRATORY DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 233. EUROPE RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 234. EUROPE RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, 2017-2032 (USD MILLION)
TABLE 235. EUROPE RESPIRATORY DISEASE TESTING MARKET SIZE, BY PULMONARY FUNCTION TESTS, 2017-2032 (USD MILLION)
TABLE 236. EUROPE RESPIRATORY DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 237. EUROPE RESPIRATORY DISEASE TESTING MARKET SIZE, BY RESPIRATORY SPECIMENS, 2017-2032 (USD MILLION)
TABLE 238. EUROPE RESPIRATORY DISEASE TESTING MARKET SIZE, BY BLOOD BASED SAMPLES, 2017-2032 (USD MILLION)
TABLE 239. EUROPE RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 240. EUROPE RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2017-2032 (USD MILLION)
TABLE 241. EUROPE RESPIRATORY DISEASE TESTING MARKET SIZE, BY VIRAL RESPIRATORY DISEASES, 2017-2032 (USD MILLION)
TABLE 242. EUROPE RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFLUENZA INFECTIONS, 2017-2032 (USD MILLION)
TABLE 243. EUROPE RESPIRATORY DISEASE TESTING MARKET SIZE, BY BACTERIAL RESPIRATORY DISEASES, 2017-2032 (USD MILLION)
TABLE 244. EUROPE RESPIRATORY DISEASE TESTING MARKET SIZE, BY FUNGAL RESPIRATORY DISEASES, 2017-2032 (USD MILLION)
TABLE 245. EUROPE RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 246. MIDDLE EAST RESPIRATORY DISEASE TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 247. MIDDLE EAST RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2017-2032 (USD MILLION)
TABLE 248. MIDDLE EAST RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 249. MIDDLE EAST RESPIRATORY DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 250. MIDDLE EAST RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 251. MIDDLE EAST RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, 2017-2032 (USD MILLION)
TABLE 252. MIDDLE EAST RESPIRATORY DISEASE TESTING MARKET SIZE, BY PULMONARY FUNCTION TESTS, 2017-2032 (USD MILLION)
TABLE 253. MIDDLE EAST RESPIRATORY DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 254. MIDDLE EAST RESPIRATORY DISEASE TESTING MARKET SIZE, BY RESPIRATORY SPECIMENS, 2017-2032 (USD MILLION)
TABLE 255. MIDDLE EAST RESPIRATORY DISEASE TESTING MARKET SIZE, BY BLOOD BASED SAMPLES, 2017-2032 (USD MILLION)
TABLE 256. MIDDLE EAST RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 257. MIDDLE EAST RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2017-2032 (USD MILLION)
TABLE 258. MIDDLE EAST RESPIRATORY DISEASE TESTING MARKET SIZE, BY VIRAL RESPIRATORY DISEASES, 2017-2032 (USD MILLION)
TABLE 259. MIDDLE EAST RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFLUENZA INFECTIONS, 2017-2032 (USD MILLION)
TABLE 260. MIDDLE EAST RESPIRATORY DISEASE TESTING MARKET SIZE, BY BACTERIAL RESPIRATORY DISEASES, 2017-2032 (USD MILLION)
TABLE 261. MIDDLE EAST RESPIRATORY DISEASE TESTING MARKET SIZE, BY FUNGAL RESPIRATORY DISEASES, 2017-2032 (USD MILLION)
TABLE 262. MIDDLE EAST RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 263. AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 264. AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2017-2032 (USD MILLION)
TABLE 265. AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 266. AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 267. AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 268. AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, 2017-2032 (USD MILLION)
TABLE 269. AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY PULMONARY FUNCTION TESTS, 2017-2032 (USD MILLION)
TABLE 270. AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 271. AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY RESPIRATORY SPECIMENS, 2017-2032 (USD MILLION)
TABLE 272. AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY BLOOD BASED SAMPLES, 2017-2032 (USD MILLION)
TABLE 273. AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 274. AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2017-2032 (USD MILLION)
TABLE 275. AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY VIRAL RESPIRATORY DISEASES, 2017-2032 (USD MILLION)
TABLE 276. AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFLUENZA INFECTIONS, 2017-2032 (USD MILLION)
TABLE 277. AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY BACTERIAL RESPIRATORY DISEASES, 2017-2032 (USD MILLION)
TABLE 278. AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY FUNGAL RESPIRATORY DISEASES, 2017-2032 (USD MILLION)
TABLE 279. AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 280. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 281. ASEAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 282. ASEAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2017-2032 (USD MILLION)
TABLE 283. ASEAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 284. ASEAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 285. ASEAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 286. ASEAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, 2017-2032 (USD MILLION)
TABLE 287. ASEAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY PULMONARY FUNCTION TESTS, 2017-2032 (USD MILLION)
TABLE 288. ASEAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 289. ASEAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY RESPIRATORY SPECIMENS, 2017-2032 (USD MILLION)
TABLE 290. ASEAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY BLOOD BASED SAMPLES, 2017-2032 (USD MILLION)
TABLE 291. ASEAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 292. ASEAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2017-2032 (USD MILLION)
TABLE 293. ASEAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY VIRAL RESPIRATORY DISEASES, 2017-2032 (USD MILLION)
TABLE 294. ASEAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFLUENZA INFECTIONS, 2017-2032 (USD MILLION)
TABLE 295. ASEAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY BACTERIAL RESPIRATORY DISEASES, 2017-2032 (USD MILLION)
TABLE 296. ASEAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY FUNGAL RESPIRATORY DISEASES, 2017-2032 (USD MILLION)
TABLE 297. ASEAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 298. GCC RESPIRATORY DISEASE TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 299. GCC RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2017-2032 (USD MILLION)
TABLE 300. GCC RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 301. GCC RESPIRATORY DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 302. GCC RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 303. GCC RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, 2017-2032 (USD MILLION)
TABLE 304. GCC RESPIRATORY DISEASE TESTING MARKET SIZE, BY PULMONARY FUNCTION TESTS, 2017-2032 (USD MILLION)
TABLE 305. GCC RESPIRATORY DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 306. GCC RESPIRATORY DISEASE TESTING MARKET SIZE, BY RESPIRATORY SPECIMENS, 2017-2032 (USD MILLION)
TABLE 307. GCC RESPIRATORY DISEASE TESTING MARKET SIZE, BY BLOOD BASED SAMPLES, 2017-2032 (USD MILLION)
TABLE 308. GCC RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 309. GCC RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2017-2032 (USD MILLION)
TABLE 310. GCC RESPIRATORY DISEASE TESTING MARKET SIZE, BY VIRAL RESPIRATORY DISEASES, 2017-2032 (USD MILLION)
TABLE 311. GCC RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFLUENZA INFECTIONS, 2017-2032 (USD MILLION)
TABLE 312. GCC RESPIRATORY DISEASE TESTING MARKET SIZE, BY BACTERIAL RESPIRATORY DISEASES, 2017-2032 (USD MILLION)
TABLE 313. GCC RESPIRATORY DISEASE TESTING MARKET SIZE, BY FUNGAL RESPIRATORY DISEASES, 2017-2032 (USD MILLION)
TABLE 314. GCC RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 315. EUROPEAN UNION RESPIRATORY DISEASE TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 316. EUROPEAN UNION RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2017-2032 (USD MILLION)
TABLE 317. EUROPEAN UNION RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 318. EUROPEAN UNION RESPIRATORY DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 319. EUROPEAN UNION RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 320. EUROPEAN UNION RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, 2017-2032 (USD MILLION)
TABLE 321. EUROPEAN UNION RESPIRATORY DISEASE TESTING MARKET SIZE, BY PULMONARY FUNCTION TESTS, 2017-2032 (USD MILLION)
TABLE 322. EUROPEAN UNION RESPIRATORY DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 323. EUROPEAN UNION RESPIRATORY DISEASE TESTING MARKET SIZE, BY RESPIRATORY SPECIMENS, 2017-2032 (USD MILLION)
TABLE 324. EUROPEAN UNION RESPIRATORY DISEASE TESTING MARKET SIZE, BY BLOOD BASED SAMPLES, 2017-2032 (USD MILLION)
TABLE 325. EUROPEAN UNION RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 326. EUROPEAN UNION RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2017-2032 (USD MILLION)
TABLE 327. EUROPEAN UNION RESPIRATORY DISEASE TESTING MARKET SIZE, BY VIRAL RESPIRATORY DISEASES, 2017-2032 (USD MILLION)
TABLE 328. EUROPEAN UNION RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFLUENZA INFECTIONS, 2017-2032 (USD MILLION)
TABLE 329. EUROPEAN UNION RESPIRATORY DISEASE TESTING MARKET SIZE, BY BACTERIAL RESPIRATORY DISEASES, 2017-2032 (USD MILLION)
TABLE 330. EUROPEAN UNION RESPIRATORY DISEASE TESTING MARKET SIZE, BY FUNGAL RESPIRATORY DISEASES, 2017-2032 (USD MILLION)
TABLE 331. EUROPEAN UNION RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 332. BRICS RESPIRATORY DISEASE TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 333. BRICS RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2017-2032 (USD MILLION)
TABLE 334. BRICS RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 335. BRICS RESPIRATORY DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 336. BRICS RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 337. BRICS RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, 2017-2032 (USD MILLION)
TABLE 338. BRICS RESPIRATORY DISEASE TESTING MARKET SIZE, BY PULMONARY FUNCTION TESTS, 2017-2032 (USD MILLION)
TABLE 339. BRICS RESPIRATORY DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2

Companies Mentioned

  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMérieux SA
  • COSMED Srl
  • Danaher Corporation
  • DiaSorin S.p.A.
  • Drägerwerk AG & Co. KGaA
  • F. Hoffmann-La Roche Ltd.
  • Fisher & Paykel Healthcare Corporation Limited
  • GE HealthCare Technologies Inc.
  • Hologic, Inc.
  • Masimo Corporation
  • Medtronic plc
  • MGC Diagnostics Corporation
  • NDD Medical Technologies
  • Owlstone Medical Ltd.
  • QIAGEN N.V.
  • QuidelOrtho Corporation
  • Randox Laboratories Ltd.
  • ResMed Inc.
  • Seegene Inc.
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
  • Verisante Technology, Inc.
  • Visby Medical, Inc.
  • Vyaire Medical Inc.

Table Information

Report AttributeDetails
No. of Pages193
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 6.34 Billion
Forecasted Market Value ( USD ) by 2032 $ 9.32 Billion
Compound Annual Growth Rate6.5%
Regions CoveredGlobal
No. of Companies Mentioned28

Related Topics

Related Reports

Acute Respiratory Disease Diagnostics Market Size, Share & Trends Analysis Report by Test, Pathogen, End-use and Region with Growth Forecasts, 2025-2033 - Product Image

Acute Respiratory Disease Diagnostics Market Size, Share & Trends Analysis Report by Test, Pathogen, End-use and Region with Growth Forecasts, 2025-2033

  • Report
  • 150 Pages
  • Global
From
Respiratory Disease Testing - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Respiratory Disease Testing - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 120 Pages
  • Global
From
Respiratory Disease Testing Market Outlook 2026-2034: Market Share, and Growth Analysis by Test Type, Disease Type, End User, Technology - Product Image

Respiratory Disease Testing Market Outlook 2026-2034: Market Share, and Growth Analysis by Test Type, Disease Type, End User, Technology

  • Report
  • 160 Pages
  • Global
From
Respiratory Disease Testing - Global Strategic Business Report - Product Image

Respiratory Disease Testing - Global Strategic Business Report

  • Report
  • 158 Pages
  • Global
From
Respiratory Disease Testing Market Report 2026 - Product Image

Respiratory Disease Testing Market Report 2026

  • Report
  • 250 Pages
  • Global
From

About the Respiratory Disease Test Market

The Respiratory Disease Test market within the context of Diagnostics is a rapidly growing sector, as respiratory diseases are among the most common illnesses worldwide. Tests for respiratory diseases are used to diagnose and monitor a variety of conditions, including asthma, chronic obstructive pulmonary disease (COPD), and pneumonia. These tests can be conducted in a variety of ways, including imaging tests, pulmonary function tests, and laboratory tests. Imaging tests such as X-rays and CT scans are used to detect abnormalities in the lungs, while pulmonary function tests measure the amount of air a person can inhale and exhale. Laboratory tests, such as sputum tests, are used to detect the presence of bacteria or viruses in the lungs. Some companies in the Respiratory Disease Test market include Abbott Laboratories, Becton Dickinson, Siemens Healthineers, Roche Diagnostics, and Thermo Fisher Scientific. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.